Platelet concentrates, from whole blood or collected by apheresis?

Transfusion and Apheresis Science

Volumn 48, Issue 2, 2013, Pages 129-131

  van der Meer, Pieter F ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ALLOIMMUNIZATION; APHERESIS; BLOOD; BLOOD BUFFY COAT; BLOOD SAFETY; CENTRIFUGATION; HUMAN; INFECTION RISK; REVIEW; THROMBOCYTE; THROMBOCYTE PRESERVATION; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY;

BLOOD BUFFY COAT; BLOOD DONORS; BLOOD PLATELETS; HUMANS; PLATELET TRANSFUSION; PLATELETPHERESIS;

EID: 84877593777     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.02.004     Document Type: Review

References (11)

1. Gulliksson H., Larsson S., Kumlien G., Shanwell A. Storage of platelets in additive solutions: effects of phosphate. Vox Sang 2000, 78:176-184.
2. Turner V.S., Hawker R.J., Mitchell S.G. Seymour mead AM. Paired in vivo and in vitro comparison of apheresis and "recovered" platelet concentrates stored for 5days. J Clin Apher 1994, 9:189-194.
3. Krailadsiri P., Seghatchian J. Are all leucodepleted platelet concentrates equivalent? Comparison of Cobe LRS Turbo, Haemonetics MCS+ LD, and filtered pooled buffy-coat-derived platelets. Vox Sang 2000, 78:171-175.
4. Li J., de Korte D., Woolum M.D., Ruane P.H., Keil S.D., Lockerbie O., et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004, 87:82-90.
5. Böck M., Rahrig S., Kunz D., Lutze G., Heim M.U. Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 2002, 12:317-324.
6. Mitchell S.G., Turner V.S., Hawker R.J., Mead A.M. A comparative study in volunteers of apheresis and buffy coat derived platelets. Platelets 1995, 6:146-151.
7. Anderson N.A., Gray S., Copplestone J.A., Chan D.C., Hamon M., Prentice A.G., et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 1997, 7:33-39.
8. Akkök C.A., Brinch L., Lauritzsen G.F., Solheim B.G., Kjeldsen-Kragh J. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sang 2007, 93:42-48.
9. Heddle N.M., Arnold D.M., Boye D., Webert K.E., Resz I., Dumont L.J. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion. 2008, 48:1447-1458.
10. Vamvakas E.C. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009, 49:2743-2758.
11. Wiltbank T.B., Giordano G.F. The safety profile of automated collections: an analysis of more than 1 million collections. Transfusion 2007, 47:1002-1005.